CLAIMS

1) A compound of Formula (I), or a pharmaceutically acceptable salt thereof,



(I)

wherein:

R^1 is selected from i) H, Me, Et, Pr, *i*-Pr, cyclopropyl, CH_2CN, CH_2F and oxetane, or ii) a C_1-C_6 alkyl group, a C_3-C_6 cycloalkyl group or a 5-membered *N*-heterocycle in each case optionally substituted with one or more substituents selected from Me, F, Cl, CN, OMe and C_1-C_3 alkyl;

R^2 is selected from H, F, Cl, D and Me;

R^3 and R^4 are each independently selected from H, Me, Et, F, Cl, optionally substituted C_1-C_3 alkyl and C_1-C_3 haloalkyl;

Y is N(Me)COMe, N(R^5)COMe, N(Me)COR^6, N(Me)COCH(OH)Me, N(Me)COCH(OR^5)R^6, N(R^5)COR^6, $CONMe_2$, CONR^{5}R^6, a 5-membered *N*-heterocycle such as 1,2,3-triazole, 1,2,4-triazole, 1,3,4-oxadiazole, 2-pyrrolidinone, 2-imidazolidinone, imidazole or pyrazole, or a 6-membered *N*-heterocycle such as 1-pyridone or pyridazine, wherein the 5- or 6-membered *N*-heterocycle is optionally substituted with a group R^5 at N or with a group R^6 at C, and Z is H, Me, Et or optionally substituted C_1-C_6 alkyl; or

Y and Z combine to form an optionally substituted 4-, 5- or 6-membered ring;

X is selected from OR^7 and NR^{8}R^9;

R^5 is selected from H, Me, optionally substituted C_1-C_6 alkyl and optionally substituted C_3-C_6 cycloalkyl;

R^6 is selected from Me, optionally substituted C_1-C_6 alkyl and optionally substituted C_3-C_6 cycloalkyl;

R^7 is Me, Et, *i*-propyl, *n*-propyl, cyclopropyl, cyclobutyl, an optionally substituted C_1-C_6 alkyl, C_3-C_6 cycloalkyl, -CH_2(C_3-C_6 cycloalkyl) or a 4-, 5- or 6-membered ring containing an heteroatom selected from O and N;

R^8 and R^9 are independently selected from H, Me and optionally substituted C_1-C_6 alkyl, or together form an optionally substituted C_3-C_6 cycloalkyl or an optionally substituted 4-, 5- or 6-membered ring containing a further heteroatom selected from O and N;

wherein the optional substituents of Z, R^3, R^4, R^5, R^6, R^7, R^8 and R^9, when present, are independently selected from OH, C_1-C_3 alkyl, C_1-C_3 alkoxy, C(O)Me, amino, NHMe, NMe_2, F or Cl.

2) A compound or pharmaceutically acceptable salt thereof according to claim 1 wherein the group R^1 is selected from



3) A compound or pharmaceutically acceptable salt thereof according to claim 1 wherein the group R^1 is selected from methyl, fluoromethyl, cyanomethyl and cyclopropyl.

4) A compound or pharmaceutically acceptable salt thereof according to any preceding claim wherein the group R^2 is H and the group R^3 is H and/or the group R^4 is H.

5) A compound or pharmaceutically acceptable salt thereof according to any preceding claim wherein the group Y is selected from N(Me)COMe, N(R^5)COMe, N(Me)COR^6, N(Me)COCH(OH)Me, N(Me)COCH(OR^5)R^6, N(R^5)COR^6, CONMe$_2$, CONR^{5}R^6, a 5-membered *N*-heterocycle such as 1,2,3-triazole, 1,2,4-triazole, 1,3,4-oxadiazole, 2-pyrrolidinone, 2-imidazolidinone, imidazole or pyrazole or a 6-membered *N*-heterocycle such as 1-pyridone or pyridazine and Z is H, Me, Et or optionally substituted C_1-C_6 alkyl.

6) A compound or pharmaceutically acceptable salt thereof according to any of claims 1 to 4 wherein the group Y is selected from



that is optionally substituted with a group R^5 at N or with a group R^6 at C, and Z is H.

7) A compound or pharmaceutically acceptable salt thereof according to any of claims 1 to 4 wherein the group Y is selected from



8) A compound or pharmaceutically acceptable salt thereof according to claim 1 that is selected from:

6-Methoxy-*N*-(1-methyl-2-oxo-1,2-dihydropyridin-3-yl)-2-((1*r*,4*r*)-4-(*N*-methylacetamido)cyclohexyl)-2*H*-indazole-5-carboxamide;

6-Methoxy-*N*-(1-methyl-2-oxo-1,2-dihydropyridin-3-yl)-2-((1*R*,2*R*)-2-methyl-4-(*N*-methylacetamido)cyclohexyl)-2*H*-indazole-5-carboxamide;

6-Methoxy-*N*-(1-methyl-2-oxo-1,2-dihydropyridin-3-yl)-2-((1*R*,2*S*,4*R*)-2-methyl-4-(*N*-methylacetamido)cyclohexyl)-2*H*-indazole-5-carboxamide;

6-Methoxy-*N*-(1-methyl-2-oxo-1,2-dihydropyridin-3-yl)-2-((1*S*,2*R*,4*S*)-2-methyl-4-(*N*-methylacetamido)cyclohexyl)-2*H*-indazole-5-carboxamide;

rel-6-Methoxy-*N*-(1-methyl-2-oxo-1,2-dihydropyridin-3-yl)-2-((1*R*,2*S*,4*S*)-2-methyl-4-(*N*-methylacetamido)cyclohexyl)-2*H*-indazole-5-carboxamide;

2-((1*R*,4*r*)-4-((*R*)-2-Hydroxy-*N*-methylpropanamido)cyclohexyl)-6-methoxy-*N*-(1-methyl-2-oxo-1,2-dihydropyridin-3-yl)-2*H*-indazole-5-carboxamide;

N-(1-(fluoromethyl)-2-oxo-1,2-dihydropyridin-3-yl)-2-((1*R*,4*r*)-4-((*R*)-2-hydroxy-*N*-methylpropanamido)cyclohexyl)-6-methoxy-2*H*-indazole-5-carboxamide;

N-(1-(Cyanomethyl)-2-oxo-1,2-dihydropyridin-3-yl)-2-((1*R*,4*r*)-4-((*R*)-2-hydroxy-*N*-methylpropanamido)cyclohexyl)-6-methoxy-2*H*-indazole-5-carboxamide;

N-(1-Cyclopropyl-2-oxo-1,2-dihydropyridin-3-yl)-2-((1*S*,4*r*)-4-((*S*)-2-hydroxy-*N*-methylpropanamido)cyclohexyl)-6-methoxy-2*H*-indazole-5-carboxamide;

N-(1-Cyclopropyl-2-oxo-1,2-dihydropyridin-3-yl)-2-((1*R*,4*r*)-4-((*R*)-2-hydroxy-*N*-methylpropanamido)cyclohexyl)-6-methoxy-2*H*-indazole-5-carboxamide;

2-((1*R*,4*r*)-4-((*R*)-2-Hydroxy-*N*-methylpropanamido)cyclohexyl)-6-methoxy-*N*-(1-(oxetan-3-yl)-2-oxo-1,2-dihydropyridin-3-yl)-2*H*-indazole-5-carboxamide;

2-((1*R*,4*r*)-4-((*R*)-2-Hydroxy-*N*-methylpropanamido)cyclohexyl)-6-methoxy-*N*-(2-oxo-1-(1*H*-pyrazol-4-yl)-1,2-dihydropyridin-3-yl)-2*H*-indazole-5-carboxamide;

2-((1*R*,4*r*)-4-((*R*)-2-Hydroxy-*N*-methylpropanamido)cyclohexyl)-6-methoxy-*N*-(1-(1-methyl-1*H*-pyrazol-4-yl)-2-oxo-1,2-dihydropyridin-3-yl)-2*H*-indazole-5-carboxamide;

2-((1*R*,4*r*)-4-((*R*)-2-Hydroxy-*N*-methylpropanamido)cyclohexyl)-6-methoxy-*N*-(1-(1-methyl-1*H*-1,2,3-triazol-4-yl)-2-oxo-1,2-dihydropyridin-3-yl)-2*H*-indazole-5-carboxamide;

2-((1*R*,4*r*)-4-((*R*)-2-Hydroxy-*N*-methylpropanamido)cyclohexyl)-6-methoxy-*N*-(1-(2-methyl-2*H*-1,2,3-triazol-4-yl)-2-oxo-1,2-dihydropyridin-3-yl)-2*H*-indazole-5-carboxamide;

6-Methoxy-*N*-(1-methyl-2-oxo-1,2-dihydropyridin-3-yl)-2-((1*r*,4*r*)-4-(2-oxopyrrolidin-1-yl)cyclohexyl)-2*H*-indazole-5-carboxamide;

6-Methoxy-*N*-(1-methyl-2-oxo-1,2-dihydropyridin-3-yl)-2-((1*r*,4*r*)-4-(3-methyl-2-oxoimidazolidin-1-yl)cyclohexyl)-2*H*-indazole-5-carboxamide;

6-Methoxy-*N*-(1-methyl-2-oxo-1,2-dihydropyridin-3-yl)-2-((5*s*,8*s*)-1-methyl-2-oxo-3-oxa-1-azaspiro[4.5]decan-8-yl)-2*H*-indazole-5-carboxamide;

6-Methoxy-*N*-(1-methyl-2-oxo-1,2-dihydropyridin-3-yl)-2-((5*r*,8*r*)-1-methyl-2-oxo-3-oxa-1-azaspiro[4.5]decan-8-yl)-2*H*-indazole-5-carboxamide;

6-Methoxy-*N*-(1-methyl-2-oxo-1,2-dihydropyridin-3-yl)-2-((1*r*,4*r*)-4-(2-oxopyridin-1(2*H*)-yl)cyclohexyl)-2*H*-indazole-5-carboxamide;

6-Methoxy-*N*-(1-methyl-2-oxo-1,2-dihydropyridin-3-yl)-2-(4-(pyridazin-3-yl)cyclohexyl)-2*H*-indazole-5-carboxamide;

2-((1*r*,4*r*)-4-(1,3,4-Oxadiazol-2-yl)cyclohexyl)-6-methoxy-*N*-(1-methyl-2-oxo-1,2-dihydropyridin-3-yl)-2*H*-indazole-5-carboxamide;

2-((1*r*,4*r*)-4-(1*H*-1,2,4-Triazol-1-yl)cyclohexyl)-6-methoxy-*N*-(1-methyl-2-oxo-1,2-dihydropyridin-3-yl)-2*H*-indazole-5-carboxamide;

2-((1*r*,4*r*)-4-(1*H*-1,2,3-Triazol-1-yl)cyclohexyl)-6-methoxy-*N*-(1-methyl-2-oxo-1,2-dihydropyridin-3-yl)-2*H*-indazole-5-carboxamide;

2-((1*r*,4*r*)-4-(2-(1-hydroxyethyl)-1*H*-imidazol-1-yl)cyclohexyl)-6-methoxy-*N*-(1-methyl-2-oxo-1,2-dihydropyridin-3-yl)-2*H*-indazole-5-carboxamide; and

2-((1*r*,4*r*)-4-(4-(2-Hydroxypropan-2-yl)-1*H*-1,2,3-triazol-1-yl)cyclohexyl)-6-methoxy-*N*-(1-methyl-2-oxo-1,2-dihydropyridin-3-yl)-2*H*-indazole-5-carboxamide;

or a pharmaceutically acceptable salt thereof.

9) A compound or pharmaceutically acceptable salt thereof according to claim 1, which is the compound *N*-(1-Cyclopropyl-2-oxo-1,2-dihydropyridin-3-yl)-2-((1*S*,4*r*)-4-((*S*)-2-hydroxy-*N*-methylpropanamido)cyclohexyl)-6-methoxy-2*H*-indazole-5-carboxamide:



,

or a pharmaceutically acceptable salt thereof.

10) A compound according to claim 1, which is the compound *N*-(1-Cyclopropyl-2-oxo-1,2-dihydropyridin-3-yl)-2-((1*S*,4*r*)-4-((*S*)-2-hydroxy-*N*-methylpropanamido)cyclohexyl)-6-methoxy-2*H*-indazole-5-carboxamide:



.

11) A pharmaceutically acceptable salt according to claim 1, which is a pharmaceutically acceptable salt of *N*-(1-Cyclopropyl-2-oxo-1,2-dihydropyridin-3-yl)-2-((1*S*,4*r*)-4-((*S*)-2-hydroxy-*N*-methylpropanamido)cyclohexyl)-6-methoxy-2*H*-indazole-5-carboxamide:



12) A pharmaceutical composition comprising a compound or a pharmaceutically acceptable salt thereof according to any of claims 1 to 11 and a pharmaceutically acceptable excipient.

13) Use of a compound or a pharmaceutically acceptable salt thereof according to any of claims 1 to 11 in the manufacture of a medicament.

14) Use according to claim 13, for the treatment of an inflammatory disease or an autoinflammatory/autoimmune disease such as systemic lupus erythematosus, rheumatoid arthritis, myositis, Sjögren's syndrome, systemic sclerosis, gout, endometriosis, atopic dermatitis and psoriasis.

15) Use according to claim 13, for the treatment of melanoma or a haematologic malignancy selected from Waldenstrom's macroglobulinemia (WM), non-Hodgkin lymphoma (NHL), diffuse large B-cell lymphoma (DLBCL), primary central nervous system lymphoma (PCNSL), Splenic Marginal Zone Lymphoma (SMZL), small lymphocytic lymphoma (SLL), leukaemias (chronic lymphocytic leukaemia (CLL)) and monoclonal gammopathy of undetermined significance (MGUS-IgM+).